Crystal structures of human and mouse ketohexokinase provide a structural basis for species- and isoform-selective inhibitor design

Rebecca Ebenhoch(Boehringer Ingelheim (Germany)), Alexander Pautsch(Boehringer Ingelheim (Germany)), Alexander Weber, Herbert Nar(Boehringer Ingelheim (Germany)), Niklas Heine(Boehringer Ingelheim (Germany)), Dirk Gottschling(Boehringer Ingelheim (Germany)), Helmut Romig(Boehringer Ingelheim (Germany)), Margit Bauer(Boehringer Ingelheim (Germany)), Jörg T. Kley(Boehringer Ingelheim (Germany)), Ingo Uphues(Boehringer Ingelheim (Germany))
Acta Crystallographica Section D Structural Biology
August 1, 2023
10.1107/s2059798323006137
Cited by 5

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285